Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography


The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.

Study Start Date

August 2015

Estimated Completion Date

August 2019


  • Device: PET/CT Scan
  • Drug: 11C-choline


  • Internal Medicine: Hematology/Oncology,Men’s Health,Nephrology/Urology
  • Urology: Oncology,Prostate
  • Family Medicine: Men`s Health,Urology
  • Oncology: Renal/Urologic
  • Physician Assistant: Hematology/Oncology,Urology

MeSH Terms

  • Positron Emission Tomography
  • Prostate Cancer

Study ID

Memorial Sloan Kettering Cancer Center -- 15-117



Trial ID


Study Type

Expanded Access

Trial Phase


Enrollment Quota

Not Listed


Memorial Sloan Kettering Cancer Center

Inclusion Criteria

  • Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible).
  • Biochemical recurrence defined as any of the following: 1. PSA ? 0.2 ng/mL in at least two sequential tests for patients treated with surgery. 2. PSA ? 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy. 3. PSA ? 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting
  • Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), or In-111 capromab pendetide scintigraphy no older than 3 months.
  • Age ? 18 years.
  • Patient must be able to tolerate PET/CT imaging.
  • Patient must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria

  • Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Memorioal Sloan Kettering Cancer Center - New York, New York 187.1 miles Heiko Schoder MD 212-639-2079 None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.